Multivessel Intervention During Primary Angioplasty Too Greedy?⁎⁎Editorials published in JACC: Cardiovascular Interventions reflect the views of the authors and do not necessarily represent the views of JACC: Cardiovascular Interventions or the American College of Cardiology. by Alfonso, Fernando
EM
D
T
F
M
P
w
(
s
n
s
S
c
m
a
r
s
i
p
a
t
i
d
f
e
w
i
n
p
p
c
r
S
r
d
t
w
f
i
e
r
i
r
o
f
f
d
t
M
u
a
e
P
I
H
m
v
f
i
v
u
a
4
p
i
5
s
2
m
I
t
a
n
a
s
c
i
i
m
w
p
p
s
c
R
*
a
t
M
J A C C : C A R D I O V A S C U L A R I N T E R V E N T I O N S V O L . 3 , N O . 1 , 2 0 1 0
© 2 0 1 0 B Y T H E A M E R I C A N C O L L E G E O F C A R D I O L O G Y F O U N D A T I O N I S S N 1 9 3 6 - 8 7 9 8 / 1 0 / $ 3 6 . 0 0
P U B L I S H E D B Y E L S E V I E R I N C . D O I : 1 0 . 1 0 1 6 / j . j c i n . 2 0 0 9 . 1 2 . 0 0 1DITORIAL COMMENT
ultivessel Intervention
uring Primary Angioplasty
oo Greedy?*
ernando Alfonso, MD, PHD
adrid, Spain
rimary angioplasty is the therapy of choice for patients
ith ST-segment elevation myocardial infarction (STEMI)
1). Continuous advancements in adjuvant antithrombotic
trategies coupled with refinements in interventional tech-
iques have led to significant improvement in procedural
uccess and long-term clinical outcomes (1). However,
TEMI patients with multivessel disease remain a major
hallenge. In this setting, different studies have shown that
ultivessel disease is a major independent predictor of
dverse prognosis (2). Current clinical practice guidelines
ecommend that in STEMI patients, only the culprit vessel
hould be initially treated unless hemodynamic compromise
s present (1). In fact, a Class III recommendation is
rovided for elective interventions on noninfarct-related
rteries during the index procedure (1).
See page 22
In the fibrinolytic era, noninvasive ischemia-detecting
ests were commonly indicated to gain useful prognostic
nsights for the triage of patients requiring invasive proce-
ures. Currently, however, even when fibrinolysis is selected
or logistic reasons, most STEMI patients undergo routine
arly angiography to evaluate coronary anatomy (1). Thus,
e are entering into a completely new scenario, where
mportant early clinical decisions are made—in a growing
umber of stable post-STEMI patients—to ensure com-
lete coronary revascularization. Notably, many of these
atients with severe multivessel disease would have been
onsidered ideal surgical candidates had they presented in a
elatively stable clinical condition. However, the recent
TEMI episode, and above all, the fact that the infarct-
elated artery has already been “fixed,” usually shift the
ecision toward repeated percutaneous interventions. Many
Editorials published in JACC: Cardiovascular Interventions reflect the views of the
uthors and do not necessarily represent the views of JACC: Cardiovascular Interven-
ions or the American College of Cardiology.v
From the Cardiovascular Institute, Clı´nico San Carlos University Hospital,
adrid, Spain. Sotirios Tsimikas, MD, served as Guest Editor for this article.imes, this paradoxical clinical decision-making process (by
hich percutaneous revascularization is systematically of-
ered to complex patients with multivessel disease and
mpaired ventricular function) is not substantiated by firm
vidence. In addition, the dilemma of whether complete
evascularization should be obtained during hospitalization
n a staged procedure, or rather some time after discharge,
emains unsettled.
Recent data suggest that with currently available technol-
gies, multivessel stenting can be readily and safely per-
ormed during primary angioplasty procedures (3–6). In
act, some provocative studies challenge current recommen-
ations and suggest that this strategy is indeed superior to
he classic approach of staged elective procedures (4,5).
ost of these studies, however, are relatively small (i.e.,
nderpowered to detect differences in major clinical events)
nd did not evaluate the influence of a widespread drug-
luting stent utilization.
resent Study
n this issue of the JACC: Cardiovascular Interventions,
annan et al. (7) examine the large database of the
andatory New York State’s Percutaneous Coronary Inter-
entions Reporting System Registry (NY-PCIRS) to gain
urther insight into appropriate revascularization strategies
n STEMI patients with multivessel disease. New York’s
ital statistics data were used to follow up local residents for
p to 42 months. Patients with prior thrombolytic therapy
nd those in cardiogenic shock were excluded. A total of
,024 STEMI patients with multivessel disease undergoing
rimary angioplasty within 24 h were analyzed. Multivessel
ntervention during the index procedure was performed in
03 (12.5%) patients. Of the remaining 3,521 patients,
taged interventions during admission were performed in
59 patients (7.4%), whereas staged procedures within 2
onths of STEMI were indicated in 538 (15.3%) patients.
nterestingly, drug-eluting stents alone were used in nearly
wo-thirds of cases. However, data on the use of thrombus
spiration devices or glycoprotein IIb/IIIa inhibitors were
ot presented. To account for imbalances in baseline char-
cteristics and potential confounders, patients were propen-
ity score-matched. For patients without hemodynamic
ompromise, culprit-vessel-only intervention during the
ndex procedure was associated with significantly lower
n-hospital mortality than multivessel intervention. Further-
ore, patients undergoing staged multivessel intervention
ithin 2 months after STEMI, but not during the index
rocedure, had a significantly lower mortality rate than
atients undergoing culprit lesion intervention alone. This
eries represents the largest systematic study with long-term
linical follow-up ever performed to address this issue.
esults indicate that, whenever possible, multivessel inter-
ention should be initially avoided during primary angio-
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33lasty, and also that in STEMI patients with multivessel
isease, a strategy aimed to achieve complete revasculariza-
ion, when addressed in staged elective procedures, is
ssociated with long-term clinical benefit.
revious Studies
any studies have suggested the benefit of multivessel
ntervention in patients with acute coronary syndromes.
owever, data on STEMI patients with multivessel disease
ndergoing primary angioplasty are sparse and results are
onflicting (2–6). Two small randomized studies focused on
his topic. Di Mario et al. (4) assigned 69 STEMI patients
ith multivessel disease to unbalanced randomization with
ulprit lesion treatment only (n  17) versus complete
ultivessel intervention (n 52). The multivessel interven-
ion group required longer procedures and larger amounts of
ontrast, but only had a trend for lower revascularization
equirements at 12 months. In a more recent trial, Politi
t al. (5) randomized 214 STEMI patients with multivessel
isease to culprit vessel angioplasty alone (n  84), simul-
aneous treatment of nonculprit vessels (n  65), or culprit
essel only followed by staged revascularization (n  65).
n-hospital mortality, unplanned rehospitalization, and re-
eat revascularization occurred more frequently in the
ulprit-vessel-only group (all p  0.05). Further, the
ulprit-vessel-only strategy emerged as an independent pre-
ictor of adverse events. Although the results of these 2
andomized studies are provocative, some may consider that
he requirement for repeat revascularization in the culprit-
nly strategy should not be considered a major adverse
vent, but rather interpreted within a global strategy in
hich closer clinical follow-up is needed. Likewise, the
ample size of these studies was grossly underpowered to detect
ifferences in death or recurrent myocardial infarction.
Therefore, data from large registries are also of major
nterest and complementary value. A subanalysis of the
ADILLAC (Controlled Abciximab and Device Investi-
ation to Lower Late Angioplasty Complication) trial (2)
howed that in patients with multivessel disease undergoing
rimary angioplasty, subsequent revascularization of
oninfarct-related arteries conferred a clear prognostic ben-
fit. More recently, Cavender et al. (6) examined the large
ataset of the U.S. National Cardiovascular Data Registry
o identify STEMI patients with multivessel disease under-
oing primary angioplasty. In-hospital mortality of 3,134
atients (10.8%) with multivessel intervention was com-
ared with that of the remaining 25,802 patients undergo-
ng single-vessel intervention only at the index procedure.
atients with multivessel intervention during primary an-
ioplasty were at higher risk and more likely presented in
ardiogenic shock. Overall, the mortality rate was higher in
atients undergoing multivessel intervention. This increased
ortality persisted after adjustment for potential confound- ars, and surprisingly, when only patients in cardiogenic
hock were analyzed. Nevertheless, clinical follow-up was
ot obtained and only in-hospital mortality was assessed. In
ddition, adjustment was performed using classical multi-
ariate logistic regression models but not propensity score
atching, so residual selection biases cannot be excluded.
urther Insights and Clinical Perspective
oronary artery disease is a diffuse process, and one-half of
TEMI patients have concomitant multivessel disease (2).
owever, data from the “real world” registry of Hannan
t al. (7) suggest that only 1 in 4 patients with STEMI and
ultivessel disease (70% stenosis in 2 major vessels)
eceive nonculprit-vessel interventions within 2 months.
herefore, actually most of these patients had incomplete
evascularization. Further studies are warranted to deter-
ine whether additional efforts to obtain complete revas-
ularization in a larger number of STEMI patients may
ranslate into improved clinical outcomes.
During primary angioplasty procedures, interventions are
sually confined to the infarct-related artery. However,
ome consider this an incomplete approach. Proponents of
nitial multivessel interventions argue that STEMI patients
ave a heightened inflammatory milieu and multiple plaque
isruptions. Plaque instability is not limited to the culprit
esion, and lack of therapy of the other lesions is associated
ith adverse events. Additionally, severe disease in noncul-
rit vessels may hamper the compensatory contractility of
emote myocardial regions characteristic of STEMI pa-
ients. Finally, early discharge may be contemplated in
atients with complete revascularization (2–6). Alterna-
ively, proponents of a culprit-vessel–only strategy empha-
ize that multivessel intervention is not initially required
ecause it may lead to prolonged interventions, contrast
verload, heart failure, and renal impairment. In addition,
onculprit lesion severity may be exaggerated as the result of
irculating catecholamine-mediated vasoconstriction, and
recise evaluation of revascularization requirements may be
ampered. Furthermore, jeopardizing remote myocardial
erritory would be of special concern in the acute phase.
inally, multivessel stenting might be associated with higher
ates of periprocedural myocardial infarction, and eventu-
lly, with increased rates of late revascularizations secondary
o restenosis (2–6) (Table 1).
In the study by Hannan et al. (7) and in most previous
bservational studies alike, the final reasons to perform
onculprit vessel interventions during the index procedure
nd proceed against current recommendations remain elu-
ive. Despite elegant and rigorous adjustments using com-
lex statistical analyses, the potential for residual bias caused
y unmeasured confounders cannot be fully discarded. Two
pposite clinical scenarios may explain the performance of
dditional interventions on nonculprit lesions. Firstly, this
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34trategy may be selected in a favorable setting. This would
e the patient in whom successful culprit vessel stenting has
een readily accomplished during a smooth procedure,
eading to Thrombolysis In Myocardial Infarction (TIMI)
oronary flow grade 3 and nearly complete ST-segment
esolution. If another easy/attractive target is identified in
his patient, the temptation to finish the procedure achieving
omplete revascularization might be high. Conversely, a
omplex, prolonged procedure required to open the culprit
esion will likely discourage the operator from further
ttempts in other vessels. In the study by Hannan et al. (7),
atients’ multivessel interventions during the index proce-
ure had less frequently an abnormal coronary flow (TIMI
ow grade 2) in the culprit lesion, suggesting easy lesions.
owever, additional data on lesion characteristics or steno-
es severity were not provided. Secondly, this aggressive
trategy also may be selected in an unfavorable setting. For
nstance, additional procedures might be pursued in hemo-
ynamically stable patients with persisting chest pain or
ignificant residual ST-segment elevation. Indeed, the per-
ormance of multivessel stenting during primary angioplasty
ay be more likely in the patient in whom procedural
uccess is not apparent. Identification and treatment of the
ulprit lesion is not always easy in patients with multivessel
isease, especially in the presence of small culprit vessels or
otal occlusions receiving collateral circulation. In some
atients, a chronic occlusion may be attempted first, and
ubsequently another vessel will be attempted when the
rror is recognized. All of these may cause delayed or
nsuccessful reperfusion and contribute to adverse progno-
Table 1. Potential Consequences of Multivessel Intervention
During Primary Angioplasty
Favorable
Ensuring adequate, complete, early revascularization
Revascularization of remote ischemic myocardial territory
Lower requirement of repeated procedures
Improvement of left ventricular function
Stabilization of additional disrupted plaques
Reduction of hospital stay
Reduction in hospital costs
Improving long-term clinical outcome (?)
Unfavorable
Prolonged procedures
Larger amount of contrast media (heart failure, renal failure)
Concerns of jeopardizing remote but critical myocardium in the acute phase
Higher rates of procedure-related myocardial infarction
Higher requirement of late procedures as the result of restenosis from
multivessel stenting
Inaccurate assessment of lesion severity/revascularization requirements
Shadowing in-hospital and long-term prognosis (?)is. Eventually, we should acknowledge that the mindset of mhe operator during primary angioplasty and the myriad of
ariables interfering with procedure course are very difficult
o measure and account for.
onclusions
he present study strongly suggests that complete revascu-
arization should be pursued in STEMI patients with
ultivessel disease. However, as recommended by current
uidelines, the culprit lesion only should be attempted
uring the index primary angioplasty procedure and com-
lete revascularization should be deferred to be achieved
ater on during staged elective procedures. Current data
uggest that during primary angioplasty, perfect is the
nemy of the good. Therefore, in this challenging scenario,
heuristic, greedy, multivessel approach does not seem to be
ustified unless hemodynamic compromise is present.
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